Publications by authors named "Jan Vesterbacka"

Claim this Profile
T
The effect of remdesivir and nirmatrelvir/ritonavir on mortality in patients hospitalized with COVID-19 during the Omicron era: an emulated target trial.
John Karlsson Valik, Pontus Hedberg, Piotr Nowak, Ola Blennow, Robert Dyrdak, Jan Vesterbacka

Clin Microbiol Infect· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metformin Treatment and Immune Reconstitution in People With HIV and Type 2 Diabetes: A Matched Retrospective Study.
Tintin Bäckdahl, Pontus Hedberg, Jan Vesterbacka, Christina Carlander, Anders Sönnerborg

Open Forum Infect Dis· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a two-year follow-up of the prospective clinical trial COVAXID.
Puran Chen, Peter Bergman, Ola Blennow, Lotta Hansson, Stephan Mielke, Jan Vesterbacka

EBioMedicine· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring the interplay between antiretroviral therapy and the gut-oral microbiome axis in people living with HIV.
Aswathy Narayanan, Oscar Kieri, Jan Vesterbacka, Lokeshwaran Manoharan, Puran Chen

Sci Rep· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HTLV in Sweden.
Jan Vesterbacka, Anna-Karin Svensson, Piotr Nowak

AIDS Rev· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Memory T cells effectively recognize the SARS-CoV-2 hypermutated BA.2.86 variant.
Thomas R Müller, Yu Gao, Jinghua Wu, Oriana Ribeiro, Puran Chen, Jan Vesterbacka

Cell Host Microbe· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The cascade of care for patients with chronic hepatitis delta in Southern Stockholm, Sweden for the past 30 years.
Habiba Kamal, Karin Lindahl, Michael Ingre, Caroline Gahrton, Kerstin Karkkonen, Jan Vesterbacka

Liver Int· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration (IMMCoVA): A randomized, controlled, open-label trial.
Jonas Sundén-Cullberg, Puran Chen, Henrike Häbel, Paul Skorup, Helena Janols, Jan Vesterbacka

PLoS One· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of the gut microbiome on immunological responses to COVID-19 vaccination in healthy controls and people living with HIV.
Shilpa Ray, Aswathy Narayanan, Jan Vesterbacka, Ola Blennow, Puran Chen

NPJ Biofilms Microbiomes· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a one-year follow-up of the prospective clinical trial COVAXID.
Puran Chen, Peter Bergman, Ola Blennow, Lotta Hansson, Stephan Mielke, Jan Vesterbacka

EBioMedicine· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Additive effects of booster mRNA vaccination and SARS-CoV-2 Omicron infection on T cell immunity across immunocompromised states.
Thomas R Müller, Takuya Sekine, Darya Trubach, Julia Niessl, Puran Chen, Jan Vesterbacka

Sci Transl Med· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of myeloid cells in system-level immunometabolic dysregulation during prolonged successful HIV-1 treatment.
Sara Svensson Akusjärvi, Shuba Krishnan, Anoop T Ambikan, Flora Mikaeloff, Sivasankaran Munusamy Ponnan, Jan Vesterbacka

AIDS· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful Combination Treatment for Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
Ola Blennow, Jan Vesterbacka, Tuulikki Tovatt, Piotr Nowak

Clin Infect Dis· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium.
Dathan M Byonanebye, Mark N Polizzotto, Bastian Neesgaard, Mario Sarcletti, Raimonda Matulionyte, Jan Vesterbacka

HIV Med· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genome-scale metabolic models for natural and long-term drug-induced viral control in HIV infection.
Anoop T Ambikan, Sara Svensson-Akusjärvi, Shuba Krishnan, Maike Sperk, Piotr Nowak, Jan Vesterbacka

Life Sci Alliance· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination.
Yu Gao, Curtis Cai, David Wullimann, Julia Niessl, Olga Rivera-Ballesteros, Jan Vesterbacka

Immunity· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence and severity of COVID-19 in adults with and without HIV diagnosis.
Pontus Hedberg, Jan Vesterbacka, Ola Blennow, Catharina Missailidis, Piotr Nowak

J Intern Med· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MAIT cell compartment characteristics are associated with the immune response magnitude to the BNT162b2 mRNA anti-SARS-CoV-2 vaccine.
Caroline Boulouis, Tobias Kammann, Angelica Cuapio, Tiphaine Parrot, Yu Gao, Jan Vesterbacka

Mol Med· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peripheral blood CD4CCR6 compartment differentiates HIV-1 infected or seropositive elite controllers from long-term successfully treated individuals.
Sara Svensson Akusjärvi, Shuba Krishnan, Bianca B Jütte, Anoop T Ambikan, Soham Gupta, Jan Vesterbacka

Commun Biol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High seroconversion rate after vaccination with mRNA BNT162b2 vaccine against SARS-CoV-2 among people with HIV - but HIV viremia matters?
Xinling Xu, Jan Vesterbacka, Soo Aleman, Piotr Nowak,

AIDS· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolic Perturbation Associated With COVID-19 Disease Severity and SARS-CoV-2 Replication.
Shuba Krishnan, Hampus Nordqvist, Anoop T Ambikan, Soham Gupta, Maike Sperk, Jan Vesterbacka

Mol Cell Proteomics· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrative proteo-transcriptomic and immunophenotyping signatures of HIV-1 elite control phenotype: A cross-talk between glycolysis and HIF signaling.
Sara Svensson Akusjärvi, Anoop T Ambikan, Shuba Krishnan, Soham Gupta, Maike Sperk, Jan Vesterbacka

iScience· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial.
Peter Bergman, Ola Blennow, Lotta Hansson, Stephan Mielke, Piotr Nowak, Jan Vesterbacka

EBioMedicine· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium.
Loveleen Bansi-Matharu, Andrew Phillips, Cristiana Oprea, Katharina Grabmeier-Pfistershammer, Huldrych F Günthard, Jan Vesterbacka

Lancet HIV· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fecal Metabolome Signature in the HIV-1 Elite Control Phenotype: Enrichment of Dipeptides Acts as an HIV-1 Antagonist but a Agonist.
Maike Sperk, Anoop T Ambikan, Shilpa Ray, Kamal Singh, Flora Mikaeloff, Jan Vesterbacka

J Virol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis